Lilly reports ACHIEVE-3 trial outcomes for type 2 diabetes

​Eli Lilly and Company has reported detailed findings from the ACHIEVE-3 Phase III trial comparing the efficacy and safety of orforglipron and oral semaglutide in adults with type 2 diabetes inadequately controlled by metformin.

The post Lilly reports ACHIEVE-3 trial outcomes for type 2 diabetes appeared first on Hospital Management.

 

Back to the Featured Stories

Featured Stories

Quantum acquires NeuWave Medical to enhance tumour ablation treatments
Mahzi doses first patient in MZ-1866 trial for Pitt Hopkins syndrome
Novo Nordisk and Vivtex collaborate for oral medicines development
Stryker unveils Synchfix EVT for flexible syndesmotic ankle fixation
Vico Therapeutics initiates patient dosing for VO659 Phase I/IIa trial

Connect with us

Whether you are a professional looking for a new job or a representative of an organization who needs workforce solutions - we are here to help.

Contact Us